^
Association details:
| Biomarker: | PD-L1 expression + CD8 negative + GZMB negative |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
4479 / 18 - Immune exhaustion of tumor microenvironment mediates crizotinib resistance in ALK rearranged advanced non small cell lung cancer
Published date:
05/15/2020
Excerpt:
Among the four groups, we found patients with PD-L1-/CD8+/GZMB+ had the best response (85.7% versus 26%, p=?), while PD-L1+/CD8-/GZMB- showed primary resistance to crizotinib had the worse outcomes (4.6 versus 18 months, p < 0.001).
